The validation of new aromatase monoclonal antibodies for immunohistochemistry--a correlation with biochemical activities in 46 cases of breast cancer.
about
Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cellsEpitope characterization of an aromatase monoclonal antibody suitable for the assessment of intratumoral aromatase activityAromatase expression in atypical ductal hyperplasia in women.CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma.In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue.Assessment of automated image analysis of breast cancer tissue microarrays for epidemiologic studies.Aromatase is phosphorylated in situ at serine-118.Differential phosphorylation of perilipin 1A at the initiation of lipolysis revealed by novel monoclonal antibodies and high content analysisLocal estrogen metabolism in epithelial ovarian cancer suggests novel targets for therapy.What do we know about the mechanisms of aromatase inhibitor resistance?New experimental models for aromatase inhibitor resistance.Aromatase inhibition 2013: clinical state of the art and questions that remain to be solvedIntratumoral localization and activity of 17β-hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer: a potent prognostic factorDevelopment of new predictive markers for endocrine therapy and resistance in breast cancer.Estrogen biosynthesis in human H295 adrenocortical carcinoma cells.Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trialAntibody validationHistopathological prognostic factors in early breast carcinoma: an evaluation of cell proliferation in carcinoma cells.Aryl hydrocarbon receptor induced intratumoral aromatase in breast cancer.The Germ Cell Gene TDRD1 as an ERG Target Gene and a Novel Prostate Cancer Biomarker.Profile of Steroid Receptors and Increased Aromatase Immunoexpression in Canine Inflammatory Mammary Cancer as a Potential Therapeutic Target.Cytoplasmic estrogen receptor β as a potential marker in human non-small cell lung carcinoma.Sex steroid receptors expression and hormone-induced cell proliferation in human osteosarcoma.Effects of Obesity and Obesity-Related Molecules on Canine Mammary Gland Tumors.Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer.
P2860
Q28261025-32CD53E8-DDE5-4AF3-B10F-1D82E342C3CDQ28472079-8600C851-5760-489C-BDD5-1E78A91436D3Q30252881-75386C14-4BE9-43AB-8FB2-24003D1DB952Q30440774-D6B12A8A-ECAB-4E2A-9AFA-C13ECE0B185BQ33468636-3AA787BB-2734-47F9-80B7-0F99686BA153Q33658005-312B914A-B6BF-4278-BFE9-260146A29B87Q33781177-60ACB5F1-582D-42A3-A364-E8AD5BF56AC2Q33798953-152EF46C-6225-41FA-B29C-880F1B8DA54AQ34584283-DC94832C-ECF5-4399-99A1-11D741A2F399Q35600183-06A70210-18F2-4C9A-A02E-0514F084C33EQ35691554-417842D5-93CD-4DFD-8F1A-FC2B9970074EQ36870346-203625C5-35B4-45F0-9E67-A0927F3EDE91Q36946008-BA52AB8B-5BEF-4E7B-BDAB-CEA391096C1BQ37048625-83FFF2CC-8FDC-464F-934F-BB853497E66FQ37157598-E32FC8AD-DE43-47A2-9100-DB92542D5A5BQ37170123-8394DDBF-38E3-4255-ACFC-FD40CB3D8734Q37226579-F5A9B7D2-519B-42E0-B2E6-FD2CDDBB62A0Q37479212-2B67D3DA-EE2D-49FC-9DFE-A8B2C5D50335Q38417070-2DC0113D-89A6-4245-9735-82E1827511EFQ38728324-D196E54C-6A29-4D11-8F28-F8B0A88D57DCQ38766041-65984B99-070B-4351-B82C-B7A281ED2156Q38792187-41E77143-4221-4759-8FF6-3AC5ECB2D5E4Q39400232-13C4EA4A-3E9A-4A87-835C-51ADF18210BFQ40035236-796A834C-CF29-45E5-8014-D70C4A5BE5F5Q51033127-40A86738-9327-4F78-9412-472BDA4A3F8BQ55365837-27025618-6D02-4AB5-80C6-37AB27AFCE51
P2860
The validation of new aromatase monoclonal antibodies for immunohistochemistry--a correlation with biochemical activities in 46 cases of breast cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The validation of new aromatas ...... in 46 cases of breast cancer.
@en
type
label
The validation of new aromatas ...... in 46 cases of breast cancer.
@en
prefLabel
The validation of new aromatas ...... in 46 cases of breast cancer.
@en
P2093
P1476
The validation of new aromatas ...... in 46 cases of breast cancer.
@en
P2093
Anderson TJ
Bhatnagar AS
Edwards DP
Silverberg SG
P356
10.1016/J.JSBMB.2005.04.027
P577
2005-05-01T00:00:00Z